StockData
Acadia Pharmaceuticals Inc logo

Acadia Pharmaceuticals Inc (ACAD) stock

ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 17/3041% below fair value
$18.75+0.61 (+3.36%)

Close on Nov 13, 2026Market cap $3.23BP/E 8.9Yield –

Earnings

Acadia Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 24, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$342.00M
+22.8% on a year earlier
EPS, Q3 FY2026
$0.31
$0.42 a year earlier
Latest guidance
Raised
Nov 4, 2026 · 5 items

Quarterly results

Revenue and earnings per share from each of Acadia Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 24, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026after the close$342.00M+22.8%$0.31Release
Q2 FY2026ended Jun 30, 2026Aug 4, 2026during market hours––$0.18Release
Q1 FY2026ended Mar 31, 2026May 6, 2026during market hours$268.00M+9.7%$0.02Release
Q4 FY2025ended Dec 31, 2025Feb 25, 2026during market hours$284.00M+9.4%$1.60Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025during market hours$278.60M+11.3%$0.42Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025during market hours$264.60M+9.3%$0.16Release
Q1 FY2025ended Mar 31, 2025May 7, 2025during market hours$244.30M+18.7%$0.11Release
Q4 FY2024ended Dec 31, 2024Feb 26, 2025during market hours$259.60M+12.4%$0.86Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024during market hours$250.40M+18.3%$0.20Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024during market hours$242.00M+46.5%$0.20Release
Q1 FY2024ended Mar 31, 2024May 8, 2024during market hours$205.80M+73.7%$0.10Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Acadia Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
DAYBUE (including all forms of trofinetide) global net product salesGAAPFY2026$505.00M – $520.00M$1.22B – $1.28BLoweredNov 4, 2026
Total revenuesGAAPFY2026$1.24B – $1.30B$1.22B – $1.28BRaisedAug 4, 2026
DAYBUE net product salesGAAPFY2026$460.00M – $490.00M–LoweredMay 6, 2026
DAYBUE net product salesGAAPFY2026$460.00M – $490.00M–LoweredFeb 25, 2026
NUPLAZID net product salesGAAPFY2026$760.00M – $790.00M–NewMay 6, 2026
NUPLAZID net product salesGAAPFY2026$760.00M – $790.00M–NewFeb 25, 2026
R&D expenseGAAPFY2026$325.00M – $340.00M$385.00M – $410.00MLoweredNov 4, 2026
R&D expenseGAAPFY2026$355.00M – $380.00M$385.00M – $410.00MLoweredAug 4, 2026
SG&A expenseGAAPFY2026$665.00M – $685.00M$660.00M – $700.00MRaisedNov 4, 2026
SG&A expenseGAAPFY2026$660.00M – $700.00M$660.00M – $700.00MRaisedAug 4, 2026

Guidance vs results

The last range Acadia Pharmaceuticals gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$1.07B – $1.10B$1.07BΣ4QWithin range
Q4 FY2023Revenue$80.00M – $87.50M$231.00MAbove range
Q3 FY2023Revenue$45.00M – $55.00M$211.70MAbove range

Guidance history

Every forecast Acadia Pharmaceuticals put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 4, 2026R&D expenseFY2026$325.00M – $340.00MLowered
Nov 4, 2026SG&A expenseFY2026$665.00M – $685.00MRaised
Nov 4, 2026DAYBUE (including all forms of trofinetide) global net product salesFY2026$505.00M – $520.00MLowered
Nov 4, 2026Total revenuesFY2026$1.27B – $1.30BRaised
Nov 4, 2026NUPLAZID net product salesFY2026$760.00M – $775.00MLowered
Aug 4, 2026SG&A expenseFY2026$660.00M – $700.00MRaised
Aug 4, 2026R&D expenseFY2026$355.00M – $380.00MLowered
Aug 4, 2026Total revenuesFY2026$1.24B – $1.30BRaised
Aug 4, 2026DAYBUE (including all forms of trofinetide) global net product salesFY2026$480.00M – $510.00MLowered
Aug 4, 2026NUPLAZID net product salesFY2026$760.00M – $790.00MLowered
May 6, 2026NUPLAZID net product salesFY2026$760.00M – $790.00MNew
May 6, 2026DAYBUE net product salesFY2026$460.00M – $490.00MLowered
May 6, 2026R&D expenseFY2026$385.00M – $410.00MLowered
May 6, 2026SG&A expenseFY2026$660.00M – $700.00MRaised
May 6, 2026Total revenuesFY2026$1.22B – $1.28BNew
Feb 25, 2026DAYBUE net product salesFY2026$460.00M – $490.00MLowered
Feb 25, 2026NUPLAZID net product salesFY2026$760.00M – $790.00MNew
Feb 25, 2026R&D expenseFY2026$385.00M – $410.00MLowered
Feb 25, 2026SG&A expenseFY2026$660.00M – $700.00MRaised
Feb 25, 2026Total revenuesFY2026$1.22B – $1.28BNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Acadia Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. News
  4. News
  5. Results
  6. Results
  7. Update
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?